Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D

Daniel M. Hartung, Kirbee A. Johnston, Adriane Irwin, Sheila Markwardt, Dennis Bourdette

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The high cost of multiple sclerosis (MS) disease-modifying therapies can negatively affect access for patients through increased payer restrictions and higher out-of-pocket spending. Our objective was to describe changes in pharmacy benefit coverage and cost-sharing amounts for MS disease-modifying therapies in the Medicare Part D program, using enrollment-weighted Prescription Drug Plan Formulary files for the period 2007-16. Among therapies available throughout the study period, the rate of prior authorization use increased from 61-66 percent of plans to 84-90 percent. The share of plans with at least one therapy available without limitations declined from 39 percent to 17 percent. The projected cumulative out-of-pocket spending for 2019 was $6,894. The therapy with the highest out-of-pocket spending was generic glatiramer acetate. Policy makers need to consider both access restrictions and a growing cost-sharing burden as potential consequences of high and rising drug prices for people with MS.

Original languageEnglish (US)
Pages (from-to)303-312
Number of pages10
JournalHealth affairs (Project Hope)
Volume38
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Medicare Part D
Multiple Sclerosis
Health Expenditures
Cost Sharing
Therapeutics
Formularies
Prescription Drugs
Administrative Personnel
Cost-Benefit Analysis
Costs and Cost Analysis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Health Policy

Cite this

Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. / Hartung, Daniel M.; Johnston, Kirbee A.; Irwin, Adriane; Markwardt, Sheila; Bourdette, Dennis.

In: Health affairs (Project Hope), Vol. 38, No. 2, 01.02.2019, p. 303-312.

Research output: Contribution to journalArticle

Hartung, Daniel M. ; Johnston, Kirbee A. ; Irwin, Adriane ; Markwardt, Sheila ; Bourdette, Dennis. / Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. In: Health affairs (Project Hope). 2019 ; Vol. 38, No. 2. pp. 303-312.
@article{e05245e7f7544059965d997ae0e47d0f,
title = "Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D",
abstract = "The high cost of multiple sclerosis (MS) disease-modifying therapies can negatively affect access for patients through increased payer restrictions and higher out-of-pocket spending. Our objective was to describe changes in pharmacy benefit coverage and cost-sharing amounts for MS disease-modifying therapies in the Medicare Part D program, using enrollment-weighted Prescription Drug Plan Formulary files for the period 2007-16. Among therapies available throughout the study period, the rate of prior authorization use increased from 61-66 percent of plans to 84-90 percent. The share of plans with at least one therapy available without limitations declined from 39 percent to 17 percent. The projected cumulative out-of-pocket spending for 2019 was $6,894. The therapy with the highest out-of-pocket spending was generic glatiramer acetate. Policy makers need to consider both access restrictions and a growing cost-sharing burden as potential consequences of high and rising drug prices for people with MS.",
author = "Hartung, {Daniel M.} and Johnston, {Kirbee A.} and Adriane Irwin and Sheila Markwardt and Dennis Bourdette",
year = "2019",
month = "2",
day = "1",
doi = "10.1377/hlthaff.2018.05357",
language = "English (US)",
volume = "38",
pages = "303--312",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "2",

}

TY - JOUR

T1 - Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D

AU - Hartung, Daniel M.

AU - Johnston, Kirbee A.

AU - Irwin, Adriane

AU - Markwardt, Sheila

AU - Bourdette, Dennis

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The high cost of multiple sclerosis (MS) disease-modifying therapies can negatively affect access for patients through increased payer restrictions and higher out-of-pocket spending. Our objective was to describe changes in pharmacy benefit coverage and cost-sharing amounts for MS disease-modifying therapies in the Medicare Part D program, using enrollment-weighted Prescription Drug Plan Formulary files for the period 2007-16. Among therapies available throughout the study period, the rate of prior authorization use increased from 61-66 percent of plans to 84-90 percent. The share of plans with at least one therapy available without limitations declined from 39 percent to 17 percent. The projected cumulative out-of-pocket spending for 2019 was $6,894. The therapy with the highest out-of-pocket spending was generic glatiramer acetate. Policy makers need to consider both access restrictions and a growing cost-sharing burden as potential consequences of high and rising drug prices for people with MS.

AB - The high cost of multiple sclerosis (MS) disease-modifying therapies can negatively affect access for patients through increased payer restrictions and higher out-of-pocket spending. Our objective was to describe changes in pharmacy benefit coverage and cost-sharing amounts for MS disease-modifying therapies in the Medicare Part D program, using enrollment-weighted Prescription Drug Plan Formulary files for the period 2007-16. Among therapies available throughout the study period, the rate of prior authorization use increased from 61-66 percent of plans to 84-90 percent. The share of plans with at least one therapy available without limitations declined from 39 percent to 17 percent. The projected cumulative out-of-pocket spending for 2019 was $6,894. The therapy with the highest out-of-pocket spending was generic glatiramer acetate. Policy makers need to consider both access restrictions and a growing cost-sharing burden as potential consequences of high and rising drug prices for people with MS.

UR - http://www.scopus.com/inward/record.url?scp=85061162098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061162098&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2018.05357

DO - 10.1377/hlthaff.2018.05357

M3 - Article

C2 - 30715973

AN - SCOPUS:85061162098

VL - 38

SP - 303

EP - 312

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 2

ER -